These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 439328)

  • 21. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana.
    Voth EA; Schwartz RH
    Ann Intern Med; 1997 May; 126(10):791-8. PubMed ID: 9148653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
    Zajicek JP; Hobart JC; Slade A; Barnes D; Mattison PG;
    J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1125-32. PubMed ID: 22791906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
    Carotenuto A; Iodice R; Petracca M; Inglese M; Cerillo I; Cocozza S; Saiote C; Brunetti A; Tedeschi E; Manganelli F; Orefice G
    Acta Neurol Scand; 2017 Apr; 135(4):442-448. PubMed ID: 27500463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
    Gras A; Broughton J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):771-779. PubMed ID: 26750641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F
    Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Trojano M
    Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
    Marinelli L; Mori L; Canneva S; Colombano F; Currà A; Fattapposta F; Bandini F; Capello E; Abbruzzese G; Trompetto C
    Int Clin Psychopharmacol; 2016 Jul; 31(4):232-9. PubMed ID: 27003093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
    Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
    Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marijuana and multiple sclerosis.
    Goodin D
    Lancet Neurol; 2004 Feb; 3(2):79-80. PubMed ID: 14746994
    [No Abstract]   [Full Text] [Related]  

  • 34. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of multiple sclerosis spasticity-associated symptoms: latest data.
    Flachenecker P
    Neurodegener Dis Manag; 2016 Dec; 6(6s):9-12. PubMed ID: 27874495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective treatment of spasticity using dronabinol in pediatric palliative care.
    Kuhlen M; Hoell JI; Gagnon G; Balzer S; Oommen PT; Borkhardt A; Janßen G
    Eur J Paediatr Neurol; 2016 Nov; 20(6):898-903. PubMed ID: 27506815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
    J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tolperisone in spasticity and muscle spasm. Tolperisone in multiple sclerosis].
    Nervenarzt; 1996 Jul; 67(7 Suppl Tolperison):1-4. PubMed ID: 9404528
    [No Abstract]   [Full Text] [Related]  

  • 40. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Fernández Ó
    Eur Neurol; 2016; 75 Suppl 1():1-3. PubMed ID: 26901342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.